MSR40 Predicting Treatment Effects of a New-to-Market Drug in Clinical Practice Based on Phase III Randomized Trial Results

Treatment effects derived from clinical trials may not be generalizable to patients treated in clinical practice who may vary in the prevalence of potential effect modifiers. We developed outcome risk prediction models in trial data to predict treatment effects in Medicare patients.